Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Exact Sciences Cor (EXAS)
Exact Sciences Cor (EXAS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Exact Sciences Cor 5505 ENDEAVOR LANE MADISON WI 53719 USA

www.exactsciences.com P: 608-535-8815

Description:

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. The company is currently working on the development of additional tests for other types of cancer, with the goal of becoming a leader in cancer screening and diagnostics. Exact Sciences currently has two of the brands in cancer diagnostics, Cologuard and Oncotype DX. Cologuard Test: This is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Oncotype DX: Genomic Health's first product, the 21-gene Oncotype DX breast cancer test is used to predict the likelihood of cancer recurrence, patient survival within 10 years of diagnosis and chemotherapy benefit for early-stage patients.

Key Statistics

Overview:

Market Capitalization, $K 10,790,202
Enterprise Value, $K 10,234,822
Shares Outstanding, K 181,531
Annual Sales, $ 2,500 M
Annual Net Income, $ -204,150 K
Last Quarter Sales, $ 646,890 K
Last Quarter Net Income, $ -49,770 K
EBIT, $ -122,230 K
EBITDA, $ 85,000 K
60-Month Beta 1.23
% of Insider Shareholders 1.30%
% of Institutional Shareholders 89.13%
Float, K 179,171
% Float 98.70%
Short Volume Ratio 0.41

Growth:

1-Year Return -12.09%
3-Year Return -51.13%
5-Year Return -30.37%
5-Year Revenue Growth 450.05%
5-Year Earnings Growth 16.91%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.27 on 02/21/24
Latest Earnings Date N/A
Earnings Per Share ttm -1.14
EPS Growth vs. Prev Year 62.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

EXAS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -6.60%
Return-on-Assets % -3.20%
Profit Margin % -8.17%
Debt/Equity 0.02
Price/Sales 4.18
Price/Cash Flow 3,378.02
Price/Book 3.31
Book Value/Share 17.39
Interest Coverage -9.37
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar